188 related articles for article (PubMed ID: 17693000)
21. Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.
Pripuzova NS; Tereshkina NV; Gmyl LV; Dzhivanyan TI; Rumyantsev AA; Romanova LIu; Mustafina AN; Lashkevich VA; Karganova GG
J Med Virol; 2009 Oct; 81(10):1777-85. PubMed ID: 19697399
[TBL] [Abstract][Full Text] [Related]
22. Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus.
Rumyantsev AA; Zhang ZX; Gao QS; Moretti N; Brown N; Kleanthous H; Delagrave S; Guirakhoo F; Collett MS; Pugachev KV
Virology; 2010 Jan; 396(2):329-38. PubMed ID: 19913267
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
[TBL] [Abstract][Full Text] [Related]
24. The neurovirulence of flaviviruses in crab-eating monkeys (Macaca fascicularis).
Angsubhakorn S; Moe JB; Latendresse JR; Ward GS; Ngamprochana M; Sahaphong S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 1986 Dec; 17(4):604-12. PubMed ID: 3033834
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.
Dayan GH; Pugachev K; Bevilacqua J; Lang J; Monath TP
Viruses; 2013 Dec; 5(12):3048-70. PubMed ID: 24351795
[TBL] [Abstract][Full Text] [Related]
26. Mimicking live flavivirus immunization with a noninfectious RNA vaccine.
Kofler RM; Aberle JH; Aberle SW; Allison SL; Heinz FX; Mandl CW
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1951-6. PubMed ID: 14769933
[TBL] [Abstract][Full Text] [Related]
27. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).
Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP
Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690
[TBL] [Abstract][Full Text] [Related]
28. Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein.
Bonaldo MC; Garratt RC; Freire MS; Galler R
Cell Biochem Biophys; 2006; 44(3):313-24. PubMed ID: 16679518
[TBL] [Abstract][Full Text] [Related]
29. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates.
McGee CE; Lewis MG; Claire MS; Wagner W; Lang J; Guy B; Tsetsarkin K; Higgs S; Decelle T
J Infect Dis; 2008 Mar; 197(5):693-7. PubMed ID: 18266603
[TBL] [Abstract][Full Text] [Related]
30. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP
J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637
[TBL] [Abstract][Full Text] [Related]
31. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations.
Yu L; Robert Putnak J; Pletnev AG; Markoff L
Vaccine; 2008 Nov; 26(47):5981-8. PubMed ID: 18805457
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
[TBL] [Abstract][Full Text] [Related]
33. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.
Bonaldo MC; Garratt RC; Marchevsky RS; Coutinho ES; Jabor AV; Almeida LF; Yamamura AM; Duarte AS; Oliveira PJ; Lizeu JO; Camacho LA; Freire MS; Galler R
J Virol; 2005 Jul; 79(13):8602-13. PubMed ID: 15956601
[TBL] [Abstract][Full Text] [Related]
34. Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis.
Ishikawa T; Widman DG; Bourne N; Konishi E; Mason PW
Vaccine; 2008 May; 26(22):2772-81. PubMed ID: 18433947
[TBL] [Abstract][Full Text] [Related]
35. Selection and analysis of mutations in an encephalomyocarditis virus internal ribosome entry site that improve the efficiency of a bicistronic flavivirus construct.
Orlinger KK; Kofler RM; Heinz FX; Hoenninger VM; Mandl CW
J Virol; 2007 Nov; 81(22):12619-29. PubMed ID: 17855533
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of attenuated Japanese encephalitis live vaccine strain ML-17.
Shah PS; Tanaka M; Khan AH; Mathenge EG; Fuke I; Takagi M; Igarashi A; Morita K
Vaccine; 2006 Jan; 24(4):402-11. PubMed ID: 16303214
[TBL] [Abstract][Full Text] [Related]
37. Live flavivirus vaccines: reasons for caution.
Seligman SJ; Gould EA
Lancet; 2004 Jun; 363(9426):2073-5. PubMed ID: 15207960
[TBL] [Abstract][Full Text] [Related]
38. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.
Higgs S; Vanlandingham DL; Klingler KA; McElroy KL; McGee CE; Harrington L; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2006 Nov; 75(5):986-93. PubMed ID: 17124001
[TBL] [Abstract][Full Text] [Related]
39. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.
Bhatt TR; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2000 Apr; 62(4):480-4. PubMed ID: 11220763
[TBL] [Abstract][Full Text] [Related]
40. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice.
Ryman KD; Xie H; Ledger TN; Campbell GA; Barrett AD
Virology; 1997 Apr; 230(2):376-80. PubMed ID: 9143294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
